Characterization of Site-Specific Glycation During Process Development of a Human Therapeutic Monoclonal Antibody

2011/02/01 by Amanda K. Miller, Amanda Miller, David M. Hambly +3 · 26 citations
Biochemistry, Genetics and Molecular Biology · Medicine · Engineering · #Advanced Glycation End Products research #Biochemical effects in animals #Biofuel production and bioconversion

paper · doi:10.1002/jps.22504

Cited by

• Effects of Buffer Composition on Site-Specific Glycation of Lysine Residues in Monoclonal Antibodies
• Rates and impact of human antibody glycation in vivo
• Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies. [europepmc]
• Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: Susceptibility vs. functionality of critical quality attributes. [europepmc]
• Impact of glycation on antibody clearance. [europepmc]
• In vitro and in vivo modifications of recombinant and human IgG antibodies. [europepmc]
• A chemical and computational approach to comprehensive glycation characterization on antibodies. [europepmc]
• Glycation of antibodies: Modification, methods and potential effects on biological functions. [europepmc]
• A Multidimensional Analytical Comparison of Remicade and the Biosimilar Remsima. [europepmc]
• Forced degradation of recombinant monoclonal antibodies: A practical guide. [europepmc]
• Quantitative analysis of glycation and its impact on antigen binding. [europepmc]
• Analytical comparability study of recombinant monoclonal antibody therapeutics. [europepmc]
• Structure, heterogeneity and developability assessment of therapeutic antibodies. [europepmc]
• Dilute-and-shoot analysis of therapeutic monoclonal antibody variants in fermentation broth: a method capability study. [europepmc]
• Macro- and Micro-Heterogeneity of Natural and Recombinant IgG Antibodies. [europepmc]
• Monitoring glycation levels of a bispecific monoclonal antibody at subunit level by ultrahigh-resolution MALDI FT-ICR mass spectrometry. [europepmc]
• A Simple Strategy to Eliminate Hexosylation Bias in the Relative Quantification of N-Glycosylation in Biopharmaceuticals. [europepmc]
• Cysteine in cell culture media induces acidic IgG1 species by disrupting the disulfide bond network. [europepmc]
• In silico prediction of post-translational modifications in therapeutic antibodies. [europepmc]
• In Vitro Reactivity of the Glucose Degradation Product 3,4-Dideoxyglucosone-3-ene (3,4-DGE) towards Abundant Components of the Human Blood Circulatory System. [europepmc]
• Improved process intermediate stability through the identification and elimination of reactive glycation residues - a monoclonal antibody case study. [europepmc]
• Attribute Analytics Performance Metrics from the MAM Consortium Interlaboratory Study. [europepmc]
• Risk-Based Control Strategies of Recombinant Monoclonal Antibody Charge Variants. [europepmc]
• Systematic characterization of lysine glucuronidation in a bispecific antibody. [europepmc]
• Effects of feeding strategies on culture performance and product quality in NISTCHO. [europepmc]
• Prediction and Characterization of Glycated Peptides and Proteins using Hydrophilic Interaction Liquid Chromatography coupled with Mass Spectrometry (HILIC-MS). [europepmc]